Paul Elliot Mann Sells 83,759 Shares of ASP Isotopes (NASDAQ:ASPI) Stock

ASP Isotopes Inc. (NASDAQ:ASPI) CEO Paul Mann sold 83,759 shares of the firm’s stock in a transaction that occurred on Friday, September 4th. The shares were sold at an average price of $4.10, for a total value of $343,411.90. Following the completion of the sale, the chief executive officer directly owned 9,328,570 shares in the company, valued at $38,247,137. This trade represents a 0.89% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Paul Elliot Mann also recently made the following trade(s):

• On Wednesday, September 2nd, Paul Mann sold 83,758 shares of ASP Isotopes stock. The stock was sold at an average price of $3.91, for a total value of $327,493.78.

ASP Isotopes Stock Up 7.7%

Shares of ASPI stock opened at $4.20 on Friday. ASP Isotopes Inc. has a 12 month low of $3.51 and a 12 month high of $14.49. The firm has a market cap of $643.90 million, a PE ratio of -3.18 and a beta of 3.59. The stock has a 50 day moving average of $4.37 and a 200-day moving average of $5.20. The company has a quick ratio of 3.85, a current ratio of 3.87 and a debt-to-equity ratio of 0.76.

ASP Isotopes (NASDAQ:ASPI) last announced its quarterly earnings data on Friday, August 14th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($0.11). ASP Isotopes had a negative return on equity of 64.99% and a negative net margin of 427.98%.The company had revenue of $5.12 million during the quarter, compared to analyst estimates of $4.47 million.

Analysts Set New Price Targets

Several research analysts have recently issued reports on ASPI shares. Wall Street Zen upgraded shares of ASP Isotopes from a “strong sell” rating to a “sell” rating in a report on Saturday, August 22nd. Weiss Ratings reiterated a “sell (d-)” rating on shares of ASP Isotopes in a research note on Wednesday, June 24th. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $13.00.

Institutional Investors Weigh In On ASP Isotopes

Institutional investors and hedge funds have recently bought and sold shares of the business. BlackRock Inc. acquired a new stake in shares of ASP Isotopes during the 2nd quarter valued at about $57,331,000. HITE Hedge Asset Management LLC bought a new stake in ASP Isotopes in the fourth quarter valued at about $2,407,000. AWM Investment Company Inc. acquired a new position in ASP Isotopes in the second quarter worth about $9,837,000. Encompass Capital Advisors LLC acquired a new position in ASP Isotopes in the first quarter worth about $30,551,000. Finally, Man Group plc bought a new position in ASP Isotopes during the second quarter worth about $5,153,000. Institutional investors own 16.80% of the company’s stock.

ASP Isotopes Company Profile

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235. ASP Isotopes Inc was incorporated in 2021 and is headquartered in Washington, District Of Columbia.